Objective: The proposed study is focussed at developing acyclovir microsponges for oral drug delivery systems. QbD was applied for better understanding of the process and to generate design space, using quality target product profile, critical quality attributes, and risk assessment. The aim of the experiment is to prepare a safe, efficacious, stable and patient compliant microsponge dosage form of Acyclovir. Materials and methods: Pre-formulation studies were carried out which helped in developing a suitable dosage form. UV, FTIR, DSC, and SEM studies were done for pre-formulation and post-formulation evaluations. QbD was applied to generate design space, using QTPP, CQA, and risk assessment. Microsponges of acyclovir were developed by 2 3 factorial designs. Three variables Drug: Polymer ratio (X1), Concentration of surfactant (X2) and Stirring speed (RPM) (X3) at two levels low and high were selected and response surface plots were generated. The microsponges were prepared by Quassi-emulsion solvent diffusion method. Various characterizations that were carried out include entrapment efficiency, percentage yield, particle size determination, in-vitro drug release studies and kinetic modelling of drug release. Statistical analyses of batches and surface response studies were done to understand the effect of various independent variables on the dependent variables. Results and Discussions: The λmax was confirmed at 251 nm by UV spectroscopy. The melting point was determined experimentally to be 246 0 C which confirms the drug to be Acyclovir. FTIR and DSC studies confirmed that the drug is Acyclovir. Eight trials were taken as per the by 2 3 factorial designs.
INTRODUCTION
Acyclovir is a potent, specific antiviral drug which is active against herpes simplex viruses' types I and II and varicella zoster virus 1 . Literature studies indicate that the oral bioavailability of acyclovir is relatively less, which is around 20-30%. Hence there is a need for enhancement of oral bioavailability of the acyclovir drug by employing various approaches. Acyclovir is available as various dosage forms in the market which includes capsules, creams, ointments, tablets and suspension. For all oral dosage forms the limiting factor of bioavailability which is poor. In order to overcome this limitation of oral delivery of Acyclovir, attempts have to be made to develop novel drug delivery systems of the same drug. The underlying aim of the proposed investigation is to augment the oral bioavailability of acyclovir by developing a microsponge drug delivery system of acyclovir which will attempt to increase the oral bioavailability of the drug. Microsponges are spherical small structures having large void spaces where there can be entrapment of the drug.
These voids are non-collapsible; hence it is better for drug entrapment and the entrapment efficiency of microsponges would be very high. The release of the drugs from the microsponges involves the movement of the drug from these non-collapsible void spaces to outside. The presence of such void spaces may enable the micrsoponges to deliver the drug slowly over a period for prolonged time 2 . As such drug delivery systems are devoid of much irritation and are capable of prolonged activity; they can enhance the patient compliance. Quality by design (QbD) is an intelligent way to bring quality into both product and process. QbD can be achieved by constructive planning of all the previous data that is accessible. Although it is based on certain amount of risks, it provides results that minimizes the risk of end product failure and enhances the chances of regulatory acceptance 3 . ICH Q8, ICH Q9 and ICH Q10 do explain the principles of QbD in the best way. They provide guidelines on science and risk based assessment, life cycle of product and various approaches in its development. It is also well known
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[55] CODEN (USA): JDDTAO fact that there can be a great deal of unpredictability in scale up of a product from research and development, although the reason for failure is not generally understood. QbD is an approach to be applied in all stages of drug discovery, production and delivery [4] [5] [6] .
MATERIALS AND METHODS

Materials
The drug Acyclovir was obtained as gift sample from Aurobindo Pharma, Hyderabad. All other chemicals that were used in the experiment were of the analytical grade.
Methods
Pre-formulation studies
Determination of melting point of Acyclovir:
Melting point of Acyclovir was determined by open capillary method.
Determination of wavelength maxima (λmax) of Acyclovir:
Determination of wavelength maxima (λmax) was done for Acyclovir.
Preparation of calibration curve for Acyclovir:
The calibration curve of Acyclovir was plotted by taking 0.1N HCl as the solvent.
Identification of Acyclovir by FT-IR Spectroscopy:
FTIR study was carried for Acyclovir.
Identification of Acyclovir by DSC Study:
The thermograph of Acyclovir was obtained by DSC.
Method of preparation of Acyclovir microsponges:
Microsponges are prepared by quasi-emulsion solvent diffusion technique. In this method external phase and internal phases are used. The internal phase is organic phase was containing drug (acyclovir), Dichloromethane, Eudragit RS100 and triethyl citrate (TEC) which is added in order to facilitate the plasticity. The external phase consisted of distilled water and polyvinyl alcohol (PVA) which acts as surfactant. Measured amounts of drug and polymer are dissolved in measured quantity of DCM. The formed solution is poured into water containing polyvinyl alcohol. Internal phase and external phases were properly mixed. This results in the solidification of the drug and its diffusion out of the liquid phases. Finally the solidified microsponges are collected by filtration. Then they are subjected to washing and drying.
Characterization of Acyclovir microsponges:
Entrapment efficiency: Drug Encapsulation efficiency =
Percentage yield:
Percentage Yield=
Drug content:
Drug content is determined by using the UV Visible spectrophotometer.
Average particle size analysis:
Malvern apparatus was used for particle size analysis.
In-vitro drug release study of microsponges:
Dissolution test was carried out to determine the in-vitro drug release profile of the prepared batches of microsponges.
Kinetics of drug release:
Kinetic release study was performed to find drug release mechanism from dissolution parameter by using different various kinetic model equations like Zero order, First order, Higuchi, Hixon-Crowell and Korsemeyer-Peppas model.
Risk Assessment to identify CQAs affecting drug product quality:
Risk assessments was done to select formulation and process variable which may affect product quality for CQAs by process characterization that defines satisfactory changes in material and process parameters. As a final point, this can result in quality assurance by process design space to understand and develop control strategy. Critical quality attributes were categorized into high, medium and low risk parameters based on knowledge space. Usually high-risk parameters are considered important for Design of Experiments as they are having more effect than others and need to be in accepting multivariate ranges. Effect of different independent variables were checked by evaluating particle size, entrapment efficiency (%), particle size and % cumulative drug release of Acyclovir microsponges formulated in preliminary trial batches. Based on that characterization, CQAs were selected which have greater effect on microsponges formulations. 
Figure 1 QbD approach
Design of Experimentation (DoE) of Acyclovir microsponges by using QbD approach:
A design space can signify formulation and process variables that affects attributes which are related to drug substance, materials, equipments and finished product quality. For this purpose, risk assessment was done based on understanding of process and formulation related parameters on microsponges' quality. Preliminary studies and later Design of Experimentation (DoE) was carried out for high risk parameters. Based on effect of critical quality attributes of target product profile, design space for obtaining robust formulation was proposed.
RESULTS AND DISCUSSIONS
Pre-formulation studies Determination of melting point of Acyclovir:
The melting point of Acyclovir was found to be 256.5 °C
Determination of wavelength maxima (λmax) of Acyclovir:
The wavelength maxima (λmax) of Acyclovir were found to be 251 nm.
Figure 2 Wavelength max (λmax) of Acyclovir
Preparation of calibration curve for Acyclovir:
Figure 3 Calibration curve for Acyclovir
Identification of Acyclovir by FT-IR Spectroscopy:
The recorded IR spectrum of Acyclovir is shown in following figure. Various batches of Acyclovir microsponges by DoE Using QbD approach were prepared according to 2 3 factorial designs which are as shown in Table 3 .
Compositions of Factorial Batches in Coded Form
Various batches of Acyclovir microsponges with Eudragit RS 100 were prepared according to 2 3 factorial designs which are as shown in Table 4 . 
Concentration of surfactant (X2)
Stirring speed (RPM) (X3) 
Statistical analysis of batches ACVMS1-ACVMS8
In factorial design, amount of drug (ACV): polymer (Eudragit RS100) ratio (X1), amount of PVA Concentration (X2), and Stirring Speed (X3) were taken as independent variables. % Yield (Y1), % E. E (Y2). Particle sizes (Y3), % CDR (Y4) were selected as dependent variables. 
CONCLUSION
The focus of the current study was to develop microsponge drug delivery system of acyclovir using QbD approach. . Literature studies indicate that the oral bioavailability of acyclovir is relatively less, which is around 20-30%. The underlying objective of the proposed investigation is to augment the oral bioavailability of acyclovir by developing a microsponge drug delivery system of acyclovir. Preformulation studies were carried out which helped in developing a suitable dosage form. UV, FTIR, DSC, and SEM studies were done for pre-formulation and post-formulation evaluations. QbD was applied to generate design space, using QTPP, CQA, and risk assessment. Microsponges of acyclovir were developed by 2 3 factorial designs. Three variables Drug: Polymer ratio (X1), Concentration of surfactant (X2) and Stirring speed (RPM) (X3) at two levels low and high were selected and response surface plots were generated. The microsponges were prepared by Quassi-emulsion solvent diffusion method. Various characterizations that were carried out include entrapment efficiency, percentage yield, particle size determination, in-vitro drug release studies and kinetic modeling of drug release. Statistical analyses of batches and surface response studies were done to understand the effect of various independent variables on the dependent variables. Lastly it was concluded that microsponges of Acyclovir using QbD approach were successfully developed.
